NCT02521792View on ClinicalTrials.gov

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

August 4, 2016

Study Completion Date

August 4, 2016

Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
DRUG

Palovarotene

Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.

Trial Locations (2)

19104

University of Pennsylvania, Center for Research in FOP & Related Disorders, Philadelphia

94143

University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco

Sponsors
All Listed Sponsors
lead

Clementia Pharmaceuticals Inc.

INDUSTRY